ArthNow Logo
ArthNow
•1 min read•
✦Reported by MoneyControl

Buy Godrej Agrovet: target of Rs 855: ICICI Securities

Buy Godrej Agrovet: target of Rs 855: ICICI Securities
Source: MoneyControl

Executive Brief • Key Highlights

Fast factual intelligence distilled for busy investors, executives, and answer bots:

  • ✓ICICI Securities recommends a buy on Godrej Agrovet with a target price of Rs 855.
  • ✓The company reported revenue of INR 30bn in Q2FY27, showing 17% growth.
  • ✓While animal feed and vegetable oil segments performed well, dairy and crop protection faced pressure.

Story at a Glance

Category
Indian Markets
Reported By
MoneyControl
Reading Speed
1 Minute(s)
Market Focus
India Economy

ICICI Securities research report on Godrej Agrovet Godrej Agrovet (GOAGRO) reported recurring EBITDA/PAT of INR 2/INR 1.2bn in Q2FY27, down 6%/up 24% YoY. Revenue grew 17% YoY to INR 30bn, driven by animal feed, vegetable oil and B2C foods, while EBITDA margin contracted to 6.7% on weakness in crop protection and dairy. Animal feed EBIT rose 32% YoY, and vegetable oil volumes (FFB +14% YoY) stayed strong, with the PKO derivatives plant commissioned on 1 Sep'26. Management retains double-digit FFB volume growth guidance for FY27/FY28. Crop protection, Astec and dairy are likely to stay under pressure in the near term, while Godrej Foods (B2C +50% YoY) and the ACI Godrej Bangladesh JV are emerging as growth drivers.   Outlook We cut FY27E/FY28E EPS by 5%/1.5%, to factor in weaker performance in dairy, poultry and crop protection segments.

🔒
Premium Content

Unlock the Full Story with ArthNow Premium

To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.

✓ Full Unabridged Reports✓ Executive Audio Briefs✓ 100% Ad-Free Reading
Verified Publication Source

MoneyControl

Read the full, original unfiltered story directly on the publisher's portal.

Visit Original Article

This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.